Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus CU 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus CU 7.
ASHLYNA vs CU-7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
The Cu-7 intrauterine device (IUD) releases copper ions, which inhibit sperm motility and viability, and alter the endometrial environment to prevent implantation.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
50 mg orally once daily
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Not applicable; intrauterine device with no systemic elimination half-life. Copper release is continuous with a rate of approximately 38 µg/day, declining over time.
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Primarily fecal (80-90%) as unabsorbed copper; negligible renal excretion (<1%).
Category C
Category C
Contraceptive
Contraceptive